Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice.

Yang JS, Kim JT, Jeon J, Park HS, Kang GH, Park KS, Lee HK, Kim S, Cho YM.

PLoS One. 2010 Nov 5;5(11):e13858. doi: 10.1371/journal.pone.0013858.

2.

A novel aminosterol reverses diabetes and fatty liver disease in obese mice.

Takahashi N, Qi Y, Patel HR, Ahima RS.

J Hepatol. 2004 Sep;41(3):391-8.

PMID:
15336441
3.

Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.

Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C.

Diabetes. 2006 Aug;55(8):2159-70.

4.

Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis.

Massart J, Robin MA, Noury F, Fautrel A, Lettéron P, Bado A, Eliat PA, Fromenty B.

Br J Pharmacol. 2012 Mar;165(5):1361-74. doi: 10.1111/j.1476-5381.2011.01580.x.

5.

Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.

Malloy VL, Perrone CE, Mattocks DA, Ables GP, Caliendo NS, Orentreich DS, Orentreich N.

Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5.

PMID:
23928105
6.

Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice.

Perfield JW 2nd, Ortinau LC, Pickering RT, Ruebel ML, Meers GM, Rector RS.

J Obes. 2013;2013:296537. doi: 10.1155/2013/296537. Epub 2013 Jan 16.

7.

iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.

Deng X, Wang J, Jiao L, Utaipan T, Tuma-Kellner S, Schmitz G, Liebisch G, Stremmel W, Chamulitrat W.

Biochim Biophys Acta. 2016 May;1861(5):449-61. doi: 10.1016/j.bbalip.2016.02.004. Epub 2016 Feb 9.

PMID:
26873633
8.

Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.

Zhang H, Shen WJ, Cortez Y, Kraemer FB, Azhar S.

Am J Physiol Gastrointest Liver Physiol. 2013 Jan 1;304(1):G72-86. doi: 10.1152/ajpgi.00328.2012. Epub 2012 Oct 25.

9.

Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.

Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W.

Hepatology. 2012 May;55(5):1369-78. doi: 10.1002/hep.25531. Epub 2012 Mar 18.

PMID:
22183915
10.

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.

Ding X, Saxena NK, Lin S, Gupta NA, Anania FA.

Hepatology. 2006 Jan;43(1):173-81. Erratum in: Hepatology. 2006 Aug;44(2):515. Gupta, Narita [corrected to Gupta, Nitika Arora].

11.

Effects of bile acid sequestration on hepatic steatosis in obese mice.

Solís N, Pizarro M, Quintero P, Arab JP, Riquelme A, Padilla O, Carrasco G, Pirola CJ, Sookoian S, Arrese M.

Ann Hepatol. 2013 Jan-2014 Feb;13(1):105-12.

12.

Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice.

Huang J, Jia Y, Fu T, Viswakarma N, Bai L, Rao MS, Zhu Y, Borensztajn J, Reddy JK.

FASEB J. 2012 Feb;26(2):628-38. doi: 10.1096/fj.11-194019. Epub 2011 Oct 18.

13.

Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.

Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J, Groen AK, Aerts JM, van Eijk M.

Hepatology. 2009 Nov;50(5):1431-41. doi: 10.1002/hep.23175.

PMID:
19731235
14.

Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.

Kim MH, Park JS, Jung JW, Byun KW, Kang KS, Lee YS.

Int J Obes (Lond). 2011 Aug;35(8):1019-30. doi: 10.1038/ijo.2010.256. Epub 2010 Dec 14.

PMID:
21157426
15.

ILDR2: an endoplasmic reticulum resident molecule mediating hepatic lipid homeostasis.

Watanabe K, Watson E, Cremona ML, Millings EJ, Lefkowitch JH, Fischer SG, LeDuc CA, Leibel RL.

PLoS One. 2013 Jun 24;8(6):e67234. doi: 10.1371/journal.pone.0067234. Print 2013.

16.

The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Hardwick RN, Flores-Keown B, Zhao F, Klimecki WT, Cherrington NJ.

Toxicol Sci. 2014 Jan;137(1):26-35. doi: 10.1093/toxsci/kft230. Epub 2013 Oct 4.

17.

Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis.

Monsénégo J, Mansouri A, Akkaoui M, Lenoir V, Esnous C, Fauveau V, Tavernier V, Girard J, Prip-Buus C.

J Hepatol. 2012 Mar;56(3):632-9. doi: 10.1016/j.jhep.2011.10.008. Epub 2011 Oct 25.

PMID:
22037024
18.

Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunction.

Ceylan-Isik AF, Sreejayan N, Ren J.

J Mol Cell Cardiol. 2011 Jan;50(1):107-16. doi: 10.1016/j.yjmcc.2010.10.023. Epub 2010 Oct 28.

19.

Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.

Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S.

Metabolism. 2012 Jul;61(7):944-53. doi: 10.1016/j.metabol.2011.10.023. Epub 2011 Dec 7.

PMID:
22154323
20.

MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.

Ohyama T, Sato K, Yamazaki Y, Hashizume H, Horiguchi N, Kakizaki S, Mori M, Kusano M, Yamada M.

World J Gastroenterol. 2014 Nov 21;20(43):16227-35. doi: 10.3748/wjg.v20.i43.16227.

Supplemental Content

Support Center